loadpatents
name:-0.035554170608521
name:-0.022157192230225
name:-0.0067059993743896
SPLAWSKI; Igor Patent Filings

SPLAWSKI; Igor

Patent Applications and Registrations

Patent applications and USPTO patent grants for SPLAWSKI; Igor.The latest application filed is for "angiopoietin-like 4 antibodies and methods of use".

Company Profile
6.23.40
  • SPLAWSKI; Igor - Winchester MA
  • Splawski; Igor - Cambridge MA
  • Splawski; Igor - Alston MA
  • Splawski; Igor - Boston MA
  • Splawski; Igor - Dorchester MA
  • Splawski; Igor - Allston MA
  • Splawski; Igor - Salt Lake City UT
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Angiopoietin-like 4 Antibodies And Methods Of Use
App 20220213181 - CEBE; Regis ;   et al.
2022-07-07
Compositions And Methods For Antibodies Targeting Epo
App 20210355206 - GHOSH; Joy Gispati ;   et al.
2021-11-18
Mrna-mediated Immunization Methods
App 20210283262 - DOMINY; John ;   et al.
2021-09-16
Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies
Grant 10,870,698 - Heldwein , et al. December 22, 2
2020-12-22
Nucleic acids encoding anti-Factor P antibodies
Grant 10,865,237 - Johnson , et al. December 15, 2
2020-12-15
Compositions And Methods For Antibodies Targeting Epo
App 20200048341 - GHOSH; Joy ;   et al.
2020-02-13
Compositions and methods for antibodies targeting complement protein C5
Grant 10,407,496 - Diefenbach-Streiber , et al. Sept
2019-09-10
Compositions and methods for antibodies targeting EPO
Grant 10,385,127 - Ghosh , et al. A
2019-08-20
Compositions And Methods For Antibodies Targeting Epo
App 20190135913 - GHOSH; Joy ;   et al.
2019-05-09
Lectin-like Oxidized Ldl Receptor 1 Antibodies And Methods Of Use
App 20190040128 - HELDWEIN; Kurt Alex ;   et al.
2019-02-07
Compositions And Methods For Antibodies Targeting Factor P
App 20180327486 - JOHNSON; Leslie Ngozi Anuna ;   et al.
2018-11-15
Compositions and methods for antibodies targeting Epo
Grant 10,106,605 - Ghosh , et al. October 23, 2
2018-10-23
Compositions comprising antibodies targeting factor P
Grant 9,988,440 - Johnson , et al. June 5, 2
2018-06-05
Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
Grant 9,982,046 - Heldwein , et al. May 29, 2
2018-05-29
Compositions and Methods for Antibodies Targeting Complement Protein C5
App 20170260260 - DIEFENBACH-STREIBER; Beate ;   et al.
2017-09-14
Lectin-like Oxidized Ldl Receptor 1 Antibodies And Methods Of Use
App 20170152313 - HELDWEIN; Kurt Alex ;   et al.
2017-06-01
LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
App 20160367638 - BYERS; Crystal ;   et al.
2016-12-22
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
Grant 9,512,222 - Heldwein , et al. December 6, 2
2016-12-06
Compositions And Methods For Antibodies Targeting Epo
App 20160280783 - GHOSH; Joy ;   et al.
2016-09-29
Compositions and methods for antibodies targeting EPO
Grant 9,365,646 - Ghosh , et al. June 14, 2
2016-06-14
Compositions and Methods for Antibodies Targeting Complement Protein C5
App 20160031975 - DIEFENBACH-STREIBER; Beate ;   et al.
2016-02-04
Compositions And Methods For Antibodies Targeting Factor P
App 20150158936 - Johnson; Leslie Ngozi Anuna ;   et al.
2015-06-11
Antibodies that bind factor P
Grant 9,051,365 - Johnson , et al. June 9, 2
2015-06-09
Lectin-like Oxidized Ldl Receptor 1 Antibodies And Methods Of Use
App 20150004168 - HELDWEIN; Kurt Alex ;   et al.
2015-01-01
Compositions and methods for antibodies targeting complement protein C5
Grant 8,883,158 - Diefenbach-Streiber , et al. November 11, 2
2014-11-11
Compositions And Methods For Antibodies Targeting Epo
App 20140199306 - GHOSH; Joy ;   et al.
2014-07-17
Compositions And Methods For Antibodies Targeting Factor P
App 20130295102 - Johnson; Leslie Ngozi Anuna ;   et al.
2013-11-07
Compositions and Methods for Antibodies Targeting Complement Protein C5
App 20130064836 - DIEFENBACH-STREIBER; Beate ;   et al.
2013-03-14
Compositions and Methods for Antibodies Targeting Complement Protein C5
App 20130022615 - DIEFENBACH-STREIBER; Beate ;   et al.
2013-01-24
Compositions and methods for antibodies targeting complement protein C5
Grant 8,241,628 - Diefenbach-Streiber , et al. August 14, 2
2012-08-14
Compositions And Methods For Antibodies Targeting Complement Protein C3b
App 20100291106 - Etemad-Gilbertson; Bijan ;   et al.
2010-11-18
C5 Antigens and Uses Thereof
App 20100166748 - Guild; Braydon Charles ;   et al.
2010-07-01
Compositions and Methods for Antibodies Targeting Complement Protein C5
App 20100034809 - Diefenbach-Streiber; Beate ;   et al.
2010-02-11
Molecules and Methods for Modulating Complement Component
App 20090175875 - ETEMAD-GILBERTSON; Bijan ;   et al.
2009-07-09
Mutations in and genomic structure of HERG--a long QT syndrome gene
Grant 7,297,489 - Keating , et al. November 20, 2
2007-11-20
Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
Grant 7,247,436 - Keating , et al. July 24, 2
2007-07-24
Common polymorphism in scn5a implicated in drug-induced cardiac arrhythmia
Grant 7,208,273 - Keating , et al. April 24, 2
2007-04-24
KVLQT1--a long QT syndrome gene
Grant 6,972,176 - Keating , et al. December 6, 2
2005-12-06
MinK-related genes, formation of potassium channels and association with cardiac arrhythmia
Grant 6,864,364 - Splawski , et al. March 8, 2
2005-03-08
Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
App 20050003439 - Keating, Mark T. ;   et al.
2005-01-06
Alterations in the long QT syndrome genes KVLQT1 and SCN5A and methods for detecting same
App 20050003445 - Splawski, Igor ;   et al.
2005-01-06
Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
App 20040235038 - Keating, Mark T. ;   et al.
2004-11-25
MinK-related genes, formation of potassium channels and association with cardiac arrhythmia
App 20040197818 - Splawski, Igor ;   et al.
2004-10-07
Alterations in the long QT syndrome genes KVLQT1 and SCN5A and methods for detecting same
Grant 6,787,309 - Splawski , et al. September 7, 2
2004-09-07
Mutations in and genomic structure of herg - along QT syndrome gene
App 20040078833 - Keating, Mark T. ;   et al.
2004-04-22
Common polymorphism in scn5a implicated in drug-induced cardiac arrhythmia
App 20030235838 - Keating, Mark T. ;   et al.
2003-12-25
KVLQT1 - a long QT syndrome gene
App 20030170708 - Keating, Mark T. ;   et al.
2003-09-11
Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
App 20030054380 - Keating, Mark T. ;   et al.
2003-03-20
Mutations in the KCNE1 gene encoding human mink which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
Grant 6,432,644 - Keating , et al. August 13, 2
2002-08-13
Alterations in the long QT syndrome genes KVLQT1 and SCN5A and methods for detecting same
App 20020061524 - Splawski, Igor ;   et al.
2002-05-23
Mutations in and genomic structure of HERG - a long QT syndrome gene
App 20010034024 - Keating, Mark ;   et al.
2001-10-25
Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene
Grant 6,274,332 - Keating , et al. August 14, 2
2001-08-14

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed